

## Supplementary data




Supplemental figure 1. Recombinant adenovirus transduction of MIN6 cells and mouse islets. (A) Representative fluorescent microscopic image of a MIN6 cell line transduced with rAd.GFP at a range of multiplicity of infection as indicated, or left non-infected (NI, 0:1) and left to culture for 48 h (scale bar = 40  $\mu$ m). (B) Percent of GFP positive MIN6 cells quantified using flow cytometry. Each point represents a well of cells, cumulated from two independent experiments. (C) Fluorescent microscopic image of isolated primary mouse islets transduced with rAd.GFP at a multiplicity of infection of 5:1, 10:1 or 15:1 and cultured for 48 hours (scale bar = 100  $\mu$ m). Representative of three independent isolations.




Supplemental figure 2. Histological analysis of CD4 and CD8 T cells in A20 and GFP expressing grafts. (A) Hematoxylin & Eosin (H&E), insulin (INS), CD8 or CD4 staining of islet allografts transduced with adenovirus encoding GFP or A20 prior to transplantation and harvested at post-operative day (POD) 18, prior to rejection of control grafts (Scale bar = 25  $\mu$ m and panel insert = 100  $\mu$ m). Data is representative of 3 GFP or A20 expressing grafts. (B) CD8 or CD4 staining of islet allografts transduced with adenovirus encoding GFP or A20 prior to transplantation and harvested at post-operative day (POD) 10. Scale bar = 25  $\mu$ m and insert panel = 100  $\mu$ m. Representative of 3 GFP or A20 expressing grafts. The average number of CD8 or CD4 positively stained cells per 40× field of view per islet graft is shown in (C). (D) CD8 or CD4

staining of long-term surviving A20 transduced islet allografts harvested at POD 100. Scale bar =  $200 \mu m$  and insert panel =  $100 \mu m$ , representative of 6 long-term surviving islet grafts.



**Supplemental figure 3. PC61 mAb treatment of wild-type mice.** C57/BL6 recipients given repeated doses of  $\alpha$ CD25, clone PC61 mAb (n = 3), or an isotype-control (n = 3) and percentage of FOXP3<sup>+</sup>CD4<sup>+</sup> T cells assessed in the blood by flow cytometry.



**Supplemental figure 4. Human A20 I325N exhibits impaired NF-κB and AP-1 suppression. (A, B)** βTC3 cells co-transfected with an NF-κB.luciferase reporter (A), or an AP-1 luciferase reporter (B) and a CMV.βgal expression construct with or without PCDNA3.1 encoding human (h) reference A20, or A20 with an I325N coding variant. Cells were stimulated with 200 U/ml TNF for 8 h or left untreated. Data represents fold change of stimulated versus non-stimulated, and representative form three independent experiments. **(C)** Immunoblot (IB) of NEMO (IKKy) immunoprecipitated (IP) lysates from βTC3 cells transfected with reference A20 or A20 I325N and IKKγ with corresponding whole-cell lysates shown. Data represents two biological replicates. **(D)** Immunoblot (IB) of A20 immunoprecipitated (IP) lysates and whole-cell lysates from βTC3 cells transfected with reference A20 or A20 I325N. Following an overnight incubation cells were stimulated with TNF for the indicated times. Membranes were probed for RIPK1, A20 or β-actin (loading control). Data represents two independent experiments. Statistical significance determined by 1-way ANOVA with Tukey's multiple-comparisons post hoc test. Error bars represent s.e.m, \**P*<0.05; \*\**P*<0.01; \*\*\*P<0.001.

## Supplemental Table 1

Gene	Primer sequence
Tnfaip3	F-5'-CCTGTCACCAACGCTCCAAG-3'
	R-5'-ATTTCCAGTCCGGTGGCAAG-3'
Ccl2	F- 5'-GGTCCCTGTCATGCTTCTGG-3'
	R- 5'-CCTGCTGGTGATCCTCT-3'
Ccl22	F-5'-AAGCCTGGCGTTGTTTTGAT-3'
	R-5'-TCCCTAGGACAGTTTATGGAGTAGCT-3'
Cd3	F-5'-GCCTCAGAAGCATGATAAGC-3'
	R-5'-CCCAGAGTGATACAGATGTC-3'
Cd80	F-5'-ATGGCTTGCAATTGTCAGTTGA-3'
	R-5'-ATCAGGAGGGTCTTCTGGGGGGGGT-3'
Cd86	F-5'-TCCAGAACTTACGCAAGCACCCA-3'
	R-5'-CAGGTTCACTGAAGTTGGCGATCAC-3'
Cph2	F- 5'-TGGACCAAACACAAACGGTTCC-3'
	R- 5'-ACATTGCGAGCAGATGGGGT-3'
Ctla4	F- 5'-GTAGCCCTGCTCACTCTTCTT-3'
	R- 5'-AGGTACAGTCCCGTGTCAAC-3'
Cxcl1	F- 5'-TGGCTGGGATTCACCTCAAG-3'
	R- 5'-TATGACTTCGGTTTGGGTGCAG-3'
Cxcl2	F- 5'-CACTCTCAAGGGCGGTCAAA-3'
	R- 5'-TCAGTTAGCCTTGCCTTTGTTCA-3'
Cxcl10	F- 5'-GACGGGCCAGTGAGAATGAG-3'
	R- 5'-GTGTGTGCGTGGCTTCACTC-3'
Foxp3	F- 5'-CCCACCTACAGGCCCTTCTC-3'
	R- 5'-GGCATGGGCATCCACAGT-3'
Icam1	F- 5'-CCATGGGAATGTCACCAGGA-3'
	R- 5'-ATCACGAGGCCCACAATGAC-3'
Ifny	F- 5'-AGCAACAGCAAGGCGAAAAA-3'
	R- 5'-AGCTCATTGAATGCTTGGCG-3'
<i>Il6</i>	F- 5'-TCCTTCCTACCCCAATTTCCAA-3'
	R- 5'-TGGATGGTCTTGGTCCTTAGCC-3'
1110	F- 5'-TGTGAAAATAAGAGCAAGGCAGTG-3'
	R- 5'-CATTCATGGCCTTGTAGACACC-3'
Tgfβ	F- 5'-AGTCGGCCTCCGCTGG-3'
	R- 5'-GCTGTCTGGAGTCCTCAGGT-3'
Tnf	F- 5'-ATGGCCCAGACCCTCACACT-3'
	R- 5'-TGGTGGTTTGCTACGACGTG-3'

Mouse primers used for qRT-PCR analysis.

## Supplemental Table 2

**	•	1 0		
Lumon	nrimara	upped to	qRT-PCR	010017/010
пши	DETITIETS	IISECETOI	$( \mathbf{n}  - \mathbf{n})$	
IIGIIIGII	primero	abea 101	gitt I CIt	analy bib.

Gene	Primer sequence
CCL2	F- 5'- AGGTGACTGGGGCATTGAT -3' R- 5'- GCCTCCAGCATGAAAGTCTC -3'
ICAM1	F- 5'- AGTTGCTCCTGCCTGGGAAC -3' R- 5'- TTTAGCTGTTGACTGCCCATCAG -3'
RPL13a	F- 5'- CAAGCGGATGAACACCAAC-3' R- 5'- TGTGGGGCAGCATACCTC -3'
TNFAIP3	F- 5'- AACGAACGGTGACGGCAAT-3' R- 5'- GAAGTCCACTTCGGGCCAT-3'
TNF	F- 5'- TCCCCTGGAAAGGACACCAT-3' R- 5'- GGGTTTGCTACAACATGGGCT-3'